Abstract
Polymeric drugs have been investigated in experimental as well as clinical settings such as SMANCS and L-asparaaginase since 1970 s. Accumulated data show that there are common characteristics among wide range of polymer therapeutics : i. e. prolonged plasma half-life, highly efficient tumor targeting capability and EPR (enhanced permeability and retention) effect. The factors involved in EPR effect are common denominators in both cancer and inflammation, indicating that EPR effect of polymer drugs can be applicable to infectious and inflammatory diseases in addition to cancer. Remarkable clinical effects of PEG-interferon α conjugates and related issues are also described as promising future prospects of polymeric drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
